General readers
Understand why legal availability is not the same as medical access.
Road to Access resources
Reference pageAccess
Clinical Care vs Retreat Pathways
A scenario resource for Marieke's access choices: clinical care, trials, private specialist care, retreat access, self-directed use, or waiting in standard care.
- Clinical route
- Regulated
- Retreat route
- Non-medical
- Access issue
- Split
Diagnosis, prescribing, monitoring, reimbursement
Legal truffle context, private payment
Safety, equity, and accountability differ
At a glance
What to take from this page
- Clinical and retreat pathways solve different problems for different users.
- Retreat access may be faster, but it is not the same as reimbursed medical care.
- Safety, affordability, accountability, and eligibility diverge across every route.
Who this helps
Clinicians and policy readers
Separate clinical governance from non-medical facilitation standards.
Investors and operators
Compare the access, liability, payment, and trust implications of each route.
Reimbursed clinical care
- Diagnosis and eligibility
- Prescriber and clinical governance
- Medical monitoring
- Potential reimbursement route
Clinical trial
- Protocol-led access
- Eligibility restrictions
- Structured monitoring
- No guarantee of post-trial access
Private specialist care
- Clinical expertise
- Private payment
- Variable reimbursement
- Different provider accountability
Retreat / non-medical route
- Legal truffle context
- Private payment
- Guide standards and consent
- Different accountability structure
Self-directed use
- Fastest practical access
- No formal screening
- No medical escalation plan
- Highest uncertainty
Wait / standard care
- Established services
- Known clinical governance
- May involve long waits
- May not resolve treatment resistance
Access pathways for Marieke
| Pathway | What it offers | Main caveat |
|---|---|---|
| Reimbursed clinical care | Diagnosis-led, medically governed, potentially equitable access | Depends on approval, HTA, workforce, sites, and payment |
| Clinical trial | Structured protocol, monitoring, contribution to evidence | Eligibility limits and uncertain access after the trial |
| Private specialist care | More clinical oversight than self-directed or retreat routes | Private payment and uneven accountability |
| Retreat / truffle pathway | Faster legal non-medical access in the Dutch context | Not the same as reimbursed treatment for a medical indication |
| Self-directed use | Lowest formal access barrier | Highest uncertainty around dose, screening, support, and safety escalation |
| Wait / standard care | Uses established mental-health services | May leave unmet need if waiting lists or treatment resistance persist |
The two scenarios answer different access questions
The hospital setting asks whether psychedelic therapy can become a reimbursed, clinically governed service. The retreat setting asks what people can already access outside ordinary medical reimbursement.
For Marieke's story, the contrast is useful because it makes the stakes visible: clinical care may be slower and more regulated, while retreat access may be faster but depends on private payment, non-medical governance, and different accountability structures.
The realistic decision tree has more than two branches
A person like Marieke may wait for standard care, seek a clinical trial, pay for private specialist care, attend a retreat, or use psychedelics without a formal care structure. Each route answers a different access problem and creates a different risk profile.
The public page should keep these pathways analytically separate. Legal availability, clinical appropriateness, quality assurance, affordability, and accountability are not interchangeable.